ResApp Files Pre-Submission Package with the US FDA

View printer-friendly version ResApp Health Limited (ASX: RAP), the developer of smartphone medical applications for the diagnosis and management of respiratory disease, today announced that it has filed a Pre-Submission package with the United States Food and Drug...

ResApp Receives Approval to Begin Adult Study

View printer-friendly version ResApp Health Limited (ASX: RAP), the developer of smartphone medical applications for the diagnosis and management of respiratory disease, is pleased to announce that it has received approval to enrol its first adult patient at the...